Brookline downgraded Intensity Therapeutics (INTS) to Hold from Buy and suspended the firm’s price target pending visibility into additional funding. A global Phase 3 open label, randomized, superiority trial is ongoing in metastatic sarcoma, evaluating INT230-6 monotherapy as an intratrumoral treatment compared to the standard of care in second and third line treatment in soft tissue sarcoma subtypes, notes the analyst, who points out that enrollment completion is expected in the first half of 2026, with data readouts expected based on the number of deaths in the trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INTS:
- Intensity Therapeutics Reports Q1 2025 Financial Results
- Intensity Therapeutics reports Q1 EPS (22c) vs. (34c) last year
- Intensity and SAKK announce EMA authorization to begin with INVINCIBLE-4
- Intensity Therapeutics announces $2.35M public offering
- Intensity Therapeutics Highlights Cancer Treatment Progress